Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. Methods: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. Results: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. Conclusions: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.
Abstract
Background/Aims: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. Methods: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. Results: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. Conclusions: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.
참고문헌 (11)
- Smith SC Jr, "AHA", ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute, 2006, pp.113, 2363~2372
- Yeomans ND, "Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin", Aliment Pharmacol Ther, 22, pp.795~801 (2005)
- Sakamoto C, "Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan", Eur J Clin Pharmacol, 62, pp.765~772 (2006)
- García Rodríguez LA, "Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies", Br J Clin Pharmacol, 52, pp.563~571 (2001)
- McQuaid KR, "Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials", Am J Med, 119, pp.624~638 (2006)
- Anderson JL, "ACC", AHA 2007 guidelines for the management of patients with unstable angina, American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina, pp.non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine, Circulation[DOI]
- Hallas J, "Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study", BMJ, 333, pp.726~ (2006)
- Delaney JA, "Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding", CMAJ, 177, pp.347~351 (2007)
- Sørensen HT, "Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin", Am J Gastroenterol, 95, pp.2218~2224 (2000)
- Bhatt DL, "ACCF", ACG, Circulation, pp.2008, 118[DOI]
- Niv Y, "Endoscopy in asymptomatic minidose aspirin consumers", Dig Dis Sci, 50, pp.78~80 (2005)